Massive Bio, a pioneer in AI-powered oncology clinical trial matching, has launched a new feature on its Patient Connect app integrated with Oracle Cerner’s electronic health record (EHR) platform. The move aims to streamline access to patient medical records and significantly accelerate the process of matching cancer patients with eligible clinical trials. The integration addresses a persistent challenge in oncology: the fragmentation of patient data across multiple healthcare systems. For patients, gathering a complete medical history is often time-consuming and difficult. For hospitals, manually screening large patient populations for clinical trial eligibility is resource-intensive and inefficient. By connecting with Cerner, Massive Bio gains access to a vast portion of the U.S. healthcare infrastructure. With Epic and Cerner together serving nearly two-thirds of all healthcare providers and over three-quarters of hospital capacity, this partnership ensures broad reach across the nation’s clinical workflows and data systems. The new Cerner application offers two key benefits. First, patients can now securely link their My Cerner Chart to their Massive Bio profile with just a few clicks. This allows them to instantly compile their full medical records, empowering them to take an active role in their care and ensuring their data is ready for analysis by Massive Bio’s advanced AI. The company’s multi-agentic neurosymbolic AI, recognized by the American Society of Clinical Oncology (ASCO), uses this data to identify potential trial matches at scale. Second, healthcare providers gain a powerful bulk data retrieval tool. Hospitals and cancer centers using Cerner can now securely process records from multiple consented patients at once, dramatically reducing the time and effort required for pre-screening. This enables research teams to identify eligible candidates across larger populations, increasing trial enrollment rates and advancing cancer research. Selin Kurnaz, Ph.D., Co-founder and CEO of Massive Bio, emphasized the importance of data accessibility. “Our mission is to ensure every cancer patient can access the best treatment options, and that starts with breaking down data silos. By integrating with Cerner, we’re giving patients control over their data and equipping hospitals with tools to accelerate life-saving research.” Dr. Arturo Loaiza-Bonilla, Co-founder and Chief Medical AI Officer, added, “For a patient, time is critical. The ability to instantly pull medical history and match it with thousands of trials can make a real difference. For hospitals, bulk analysis means more patients can be offered trial opportunities, improving outcomes and accelerating progress.” The Massive Bio Cerner application is now available to patients and healthcare systems using the Cerner platform. About Massive Bio: Founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, Massive Bio leverages AI and real-world data to transform the pharmaceutical value chain. The company enhances patient access to advanced treatments, streamlines clinical trial recruitment, and supports research innovation. A founding member of the CancerX public-private partnership and participant in the White House Cancer Moonshot initiative, Massive Bio has received recognition from the National Cancer Institute and operates in 17 countries with over 100 employees worldwide. For more information, visit www.massivebio.com.